This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ASCO® 2020
Presentations

Brentuximab Vedotin | Lymphoma | Abstract TPS8069
Frontline brentuximab vedotin in Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma for older patients and those with comorbidities

Brentuximab Vedotin | Lymphoma | Abstract 8032
Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients

Brentuximab Vedotin | Lymphoma | Abstract 8013
Nivolumab and brentuximab vedotin (BV) based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis

Brentuximab Vedotin | Lymphoma | Abstract TPS8068
Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced stage Hodgkin lymphoma (Trial in Progress)
_2020-05-13_Final.png)
Enfortumab Vedotin | Urothelial Carcinoma | Abstract 5044
Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Enfortumab Vedotin | Urothelial Carcinoma | Abstract TPS5092
Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab for locally advanced or metastatic urothelial carcinoma

Enfortumab Vedotin | Urothelial Carcinoma | Abstract TPS3647
EV-202: A Phase 2 Study of Enfortumab Vedotin in Patients With Select Previously Treated Locally Advanced or Metastatic Solid Tumors

Tucatinib | Breast Cancer | Abstract 1043/128
Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)

Tucatinib | Breast Cancer | Abstract 1005
Tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)

Tisotumab Vedotin | Cervical Cancer | Abstract TPS6095
Phase 1b/2 trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024)

Ladiratuzumab Vedotin | Breast Cancer | TPS1104
SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer

SGN-CD228A | Solid Tumors | Abstract TPS3652
SGN228-001: A phase 1 open-label dose escalation and expansion study of SGN-CD228A in select advanced solid tumors

SEA-CD40 | Pancreatic Cancer | Abstract TPS4671
Phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC)
Videos
Tucatinib | Breast Cancer | Abstract 1005
Tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)
Tucatinib | Breast Cancer | Abstract 1043/128
Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)